Huah Shin Ng
Cited by
Cited by
Comorbidity, physical and mental health among cancer patients and survivors: an Australian population‐based study
HS Ng, D Roder, B Koczwara, A Vitry
Asia‐Pacific Journal of Clinical Oncology 14 (2), e181-e192, 2018
Patterns of comorbidities in women with breast cancer: a Canadian population-based study
HS Ng, A Vitry, B Koczwara, D Roder, ML McBride
Cancer Causes & Control 30, 931-941, 2019
Assessment of the therapeutic value of new medicines marketed in Australia
AI Vitry, NH Shin, P Vitre
Journal of pharmaceutical policy and practice 6, 1-6, 2013
Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study
HS Ng, B Koczwara, D Roder, A Vitry
Prostate cancer and prostatic diseases 21 (3), 403-410, 2018
Comorbidities in Australian women with hormone‐dependent breast cancer: a population‐based analysis
HS Ng, B Koczwara, DM Roder, T Niyonsenga, AI Vitry
Medical Journal of Australia 208 (1), 24-28, 2018
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review
HS Ng, CL Rosenbult, H Tremlett
Expert Opinion on Drug Safety 19 (9), 1069-1094, 2020
Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics
E Kamma, W Lasisi, C Libner, HS Ng, JR Plemel
Journal of Neuroinflammation 19 (1), 45, 2022
Changes in the prevalence of comorbidity in the Australian population with cancer, 2007–2014
HS Ng, B Koczwara, D Roder, A Vitry
Cancer Epidemiology 54, 56-62, 2018
Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study
HS Ng, B Koczwara, D Roder, T Niyonsenga, A Vitry
Journal of comorbidity 8 (1), 16-24, 2018
Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting
HS Ng, F Zhu, E Kingwell, Y Zhao, S Yao, O Ekuma, LW Svenson, ...
Expert Review of Neurotherapeutics 21 (1), 131-140, 2021
Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis
G Liang, J Chai, HS Ng, H Tremlett
Multiple Sclerosis and Related Disorders, 102566, 2020
Disease-modifying drugs for multiple sclerosis and subsequent health service use
HS Ng, F Zhu, E Kingwell, Y Zhao, S Yao, O Ekuma, LW Svenson, ...
Multiple Sclerosis Journal 28 (4), 583-596, 2022
Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study
HS Ng, E Kingwell, F Zhu, T Zhang, RA Marrie, R Carruthers, H Tremlett
Multiple Sclerosis Journal 27 (2), 239-249, 2021
Patterns of health service utilisation among the Australian population with cancer compared with the general population
HS Ng, B Koczwara, D Roder, RJ Chan, A Vitry
Australian Health Review 44 (3), 470-479, 2019
Multiple sclerosis incidence: A systematic review of change over time by geographical region
J Lane, HS Ng, C Poyser, RM Lucas, H Tremlett
Multiple Sclerosis and Related Disorders 63, 103932, 2022
Prevalence of Comorbidities and Health Status among Current Cancer and Cancer Survivors: An Australian Population-Based Study
HS Ng, D Roder, A Vitry
Value in Health 19 (7), A884-A885, 2016
Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population
HS Ng, J Graf, F Zhu, E Kingwell, O Aktas, P Albrecht, HP Hartung, ...
Frontiers in Immunology 12, 5930, 2022
Polypharmacy and multiple sclerosis: A population-based study
A Chertcoff, HS Ng, F Zhu, Y Zhao, H Tremlett
Multiple Sclerosis Journal, 13524585221122207, 2022
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
HS Ng, F Zhu, E Kingwell, S Yao, O Ekuma, C Evans, JD Fisk, RA Marrie, ...
Neurology-Neuroimmunology Neuroinflammation 9 (5), 2022
Women's health in multiple sclerosis: a scoping review
L Ross, HS Ng, J O'Mahony, MP Amato, JA Cohen, MP Harnegie, ...
Frontiers in neurology 12, 2511, 2022
The system can't perform the operation now. Try again later.
Articles 1–20